Literature DB >> 16320738

An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion.

M Nakamura1, M Endo, K Murakami, H Konno, K Fujihara, Y Itoyama.   

Abstract

We report a case of neuromyelitis optica (NMO) with a large cerebral lesion. The patient had an episode of fever and consciousness disturbance with a tumefactive frontal white matter lesion at age 43, and then repeated bilateral optic neuritis and transverse myelitis until she died at age 63. Histopathological examinations revealed that marked tissue destruction, cavities and inflammatory changes typical of NMO were seen in the cerebrum as well as the optic nerves and spinal cord. This is the first autopsied case of NMO with a tumefactive cerebral lesion that later became cavitary.

Entities:  

Mesh:

Year:  2005        PMID: 16320738     DOI: 10.1191/1352458505ms1236cr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

2.  Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study.

Authors:  M Nakamura; I Miyazawa; K Fujihara; I Nakashima; T Misu; S Watanabe; T Takahashi; Y Itoyama
Journal:  J Neurol       Date:  2008-02-04       Impact factor: 4.849

3.  Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis.

Authors:  Yuko Shimizu; Kazumasa Yokoyama; Tatsuro Misu; Toshiyuki Takahashi; Kazuo Fujihara; Seiji Kikuchi; Yasuto Itoyama; Makoto Iwata
Journal:  J Neurol       Date:  2007-11-21       Impact factor: 4.849

Review 4.  Update on neuromyelitis optica: natural history and management.

Authors:  Panitha Jindahra; T Plant
Journal:  Eye Brain       Date:  2012-03-26

5.  White matter atrophy and cognitive dysfunctions in neuromyelitis optica.

Authors:  Frederic Blanc; Vincent Noblet; Barbara Jung; François Rousseau; Felix Renard; Bertrand Bourre; Nadine Longato; Nadjette Cremel; Laure Di Bitonto; Catherine Kleitz; Nicolas Collongues; Jack Foucher; Stephane Kremer; Jean-Paul Armspach; Jerome de Seze
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

6.  Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.

Authors:  Jens Harmel; Marius Ringelstein; Jens Ingwersen; Christian Mathys; Norbert Goebels; Hans-Peter Hartung; Sven Jarius; Orhan Aktas
Journal:  BMC Neurol       Date:  2014-12-17       Impact factor: 2.474

7.  An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab.

Authors:  Ismael Sánchez Gomar; María Díaz Sánchez; Antonio José Uclés Sánchez; José Luis Casado Chocán; Reposo Ramírez-Lorca; Ana Serna; Javier Villadiego; Juan José Toledo-Aral; Miriam Echevarría
Journal:  BMC Neurol       Date:  2014-07-01       Impact factor: 2.474

8.  A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; So-Young Huh; Jae-Won Hyun; In Hye Jeong; Sang Hyun Lee; AeRan Joung; Ho Jin Kim
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

9.  Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.